Media headlines about Digirad (NASDAQ:DRAD) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Digirad earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 47.172187226858 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
NASDAQ:DRAD opened at $1.40 on Friday. Digirad has a 12 month low of $1.35 and a 12 month high of $5.35. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.51 and a quick ratio of 1.18.
Digirad (NASDAQ:DRAD) last released its earnings results on Friday, February 23rd. The medical equipment provider reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.19). Digirad had a negative net margin of 30.19% and a positive return on equity of 0.32%. The business had revenue of $30.92 million for the quarter.
Separately, ValuEngine downgraded Digirad from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st.
In other Digirad news, insider Matthew G. Molchan acquired 25,000 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was purchased at an average price of $2.14 per share, for a total transaction of $53,500.00. Following the acquisition, the insider now owns 77,819 shares in the company, valued at approximately $166,532.66. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Cannell Capital Llc acquired 65,508 shares of the firm’s stock in a transaction dated Tuesday, January 23rd. The shares were acquired at an average price of $2.65 per share, with a total value of $173,596.20. The disclosure for this purchase can be found here. 11.90% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/digirad-drad-receives-daily-news-sentiment-score-of-0-08.html.
Digirad Company Profile
Digirad Corporation provides healthcare solutions in the United States. It operates through Diagnostic Services, Mobile Healthcare, and Diagnostic Imaging segments. The Diagnostic Services segment provides nuclear and ultrasound imaging services to physicians who perform nuclear imaging, echocardiography, vascular or general ultrasound tests, imaging systems, radiopharmaceuticals, and licensing services, as well as offers remote cardiac event monitoring services.
Receive News & Ratings for Digirad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad and related companies with MarketBeat.com's FREE daily email newsletter.